



ASX/MEDIA RELEASE

10th April 2017

Update on Proposed \$30 million Share Buy-Back

Sydney, Australia; 10th April 2017 – Sirtex Medical Limited (ASX:SRX) today announces the proposed on-market share buy-back due to commence on 17th April 2017 has been delayed pending the outcome of an injunction application filed by the applicant in the Federal Court of Australia. A hearing on this matter is anticipated to take place on 26th May. Once a decision on the injunction is known, Sirtex will update the market accordingly. If the injunction is not successful at that time, Sirtex intends to commence its buy-back following the release of major clinical data at the ASCO Annual Meeting from 2nd-6th June 2017.

An amended Appendix 3D is attached.

The Company has filed a stay application in relation to the previously announced class action. The stay application is listed for hearing on 15th -16th August 2017.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at 1,060 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information, please contact:

Investor Enquiries:

Mr Darren Smith
CFO & Company Secretary
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

Head Office

Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas

300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa

Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific

50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

Appendix 3D

Changes relating to buy-back (except minimum holding buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/9/99. Origin: Appendix 7B. Amended 13/3/2000, 30/9/2001, 11/01/10

Name of entity

ABN/ARSN

SIRTEX MEDICAL LIMITED

35 078 166 122

We (the entity) give ASX the following information.

- 1 Date that an Appendix 3C or the last Appendix 3D was given to ASX

13 March 2017

Information about the change

Complete each item for which there has been a change and items 9 and 10.

Column 1

(Details announced to market in Appendix 3C or last Appendix 3D)

Column 2

(Details of change to buy-back proposals)

On-market buy-back

- 2 Name of broker who will act on the company's behalf

- 3 Deleted 30/9/2001.

- 4 If the company/trust intends to buy back a maximum number of shares/units – that number

Note: This requires a figure to be included, not a percentage. The reference to a maximum number is to the total number including shares/units already bought back and shares/units remaining to be bought back. If the total has not changed, the item does not need to be completed.

⁺ See chapter 19 for defined terms.

Appendix 3D

Changes relating to buy-back

| | Column 1 (Details announced to market in Appendix 3C or last Appendix 3D) | Column 2 (Details of change to buy-back proposals) |
|---|--|--|
| 5 If the company/trust intends to buy back a maximum number of shares/units – the number remaining to be bought back | | |
| 6 If the company/trust intends to buy-back shares/units within a period of time – that period of time; if the company/trust intends that the buy-back be of unlimited duration - that intention | <p>The Company intends to buy-back shares in the period 17 April 2017 to 8 September 2017 (inclusive) or earlier if the maximum number of shares in item 11 above is bought back prior to that date.</p> <p>The Company reserves the right to suspend or terminate the buy-back at any time.</p> | <p>The Company intends to buy-back shares in the period 7 June 2017 to 8 September 2017 (inclusive) or earlier if the maximum number of shares in item 11 above is bought back prior to that date. The commencement date assumes a decision from the Federal Court hearing on an injunction filed by the Applicant, scheduled for 26 May 2017 and presentation of major clinical data at the ASCO Annual Meeting from 2-6 June 2017.</p> <p>The Company reserves the right to suspend or terminate the buy-back at any time.</p> |
| 7 If the company/trust intends to buy back shares/units if conditions are met – those conditions | | |

⁺ See chapter 19 for defined terms.

All buy-backs

8 Any other change

| | |
|--|--|
| | |
|--|--|

9 Reason for change

To await the outcome in the Federal Court of an injunction filed against the buy-back and following the release of clinical study data at the ASCO Annual Meeting as detailed in the ASX release dated 10 April 2017.

10 Any other information material to a shareholder's/unitholder's decision whether to accept the offer (*eg, details of any proposed takeover bid*)

| |
|--|
| |
|--|

Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.

or, for trusts only:

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.

⁺ See chapter 19 for defined terms.

Appendix 3D
Changes relating to buy-back

2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:


.....
(Director/Company secretary)

Date: 10 April 2017

Print name: Darren Smith

== == == == ==

⁺ See chapter 19 for defined terms.